TNSN98090A1 - Formulations pharmaceutiques contenant du voriconazole, et procede pour leur preparation. - Google Patents
Formulations pharmaceutiques contenant du voriconazole, et procede pour leur preparation.Info
- Publication number
- TNSN98090A1 TNSN98090A1 TNTNSN98090A TNSN98090A TNSN98090A1 TN SN98090 A1 TNSN98090 A1 TN SN98090A1 TN TNSN98090 A TNTNSN98090 A TN TNSN98090A TN SN98090 A TNSN98090 A TN SN98090A TN SN98090 A1 TNSN98090 A1 TN SN98090A1
- Authority
- TN
- Tunisia
- Prior art keywords
- preparation
- pharmaceutical formulations
- formulations containing
- formulation
- voriconazole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'INVENTION CONCERNE UNE FORMULATION PHARMACEUTIQUE COMPRENANT DU VORICONAZOLE, OU UN DE SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES, ET UN DERIVE DE CYCLODEXTRINE DE FORMULE I, DANS LAQUELLE R1a-g, R2a-g et R3a-g REPRESENTENT INDEPENDAMMENT UN GROUPE OH OU O (CH2)4SO3H, SOUS RESERVE QU'AU MOINS UN DES GROUPE R1a-g REPRESENTE UN GROUPE O (CH2)4SO3H, OU UN DES SES SELS PHARMACEUTIQUEMENT ACCEPTABLES. LA FORMULATION, A L'ETAT DE SOLUTION AQUEUSE, PEUT ETRE LYOPHILISEE. APPLICATION : UTILISATION D'UNE TELLE FORMULATION AQUEUSE, INTRAVEINEUSE OU INTRAMUSCULAIRE, AYANT UNE PLUS GRANDE DUREE DE CONSERVATION.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9713149.4A GB9713149D0 (en) | 1997-06-21 | 1997-06-21 | Pharmaceutical formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN98090A1 true TNSN98090A1 (fr) | 2005-03-15 |
Family
ID=10814734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNTNSN98090A TNSN98090A1 (fr) | 1997-06-21 | 1998-06-17 | Formulations pharmaceutiques contenant du voriconazole, et procede pour leur preparation. |
Country Status (48)
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9818258D0 (en) * | 1998-08-21 | 1998-10-14 | Pfizer Ltd | Antifungal compositions |
PE20020300A1 (es) | 2000-08-22 | 2002-05-10 | Pharmacia Corp | Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco |
AR031135A1 (es) | 2000-10-10 | 2003-09-10 | Upjohn Co | Composiciones de antibiotico topico para el tratamiento de infecciones oculares |
RU2342931C2 (ru) * | 2002-08-20 | 2009-01-10 | Бристол-Маерс Сквибб Компани | Состав на основе комплекса арипипразола |
GB0327390D0 (en) * | 2003-11-25 | 2003-12-31 | Pfizer Ltd | Pharmaceutical formulations |
WO2005055952A2 (fr) * | 2003-12-08 | 2005-06-23 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions anticancereuses synergiques |
CA2572223C (fr) | 2004-06-25 | 2014-08-12 | The Johns Hopkins University | Inhibiteurs d'angiogenese |
US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
WO2007047253A2 (fr) * | 2005-10-11 | 2007-04-26 | Eastman Chemical Company | Formulations pharmaceutiques de cyclodextrines et composes antifongiques de type azole |
AR061889A1 (es) | 2006-07-13 | 2008-10-01 | Medichem Sa | Proceso mejorado para la preparacion de voriconazol |
CN1919846B (zh) * | 2006-09-14 | 2013-01-02 | 大道隆达(北京)医药科技发展有限公司 | 伏立康唑及其药用盐、中间体的一种新定向合成制备方法 |
BG1110U1 (bg) * | 2007-06-19 | 2008-09-30 | Рудолф ПОДЛИПСКИ | Отоплителен съд за експресно локално загряване навода |
EP2018866A1 (fr) * | 2007-07-27 | 2009-01-28 | Sandoz AG | Compositions pharmaceutiques contenant du voriconazole |
US8192721B2 (en) * | 2007-12-13 | 2012-06-05 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing toxicity associated with gadolinium-based contrast agents |
US20110224232A1 (en) * | 2008-05-06 | 2011-09-15 | Board Of Regents, The University Of Texas System | Treatment of Pulmonary Fungal Infection With Voriconazole via Inhalation |
MX2010013363A (es) * | 2008-06-06 | 2011-03-03 | Glenmark Pharmaceuticals Ltd | Formulacion topica estable contiene voriconazol. |
CN101390825B (zh) * | 2008-10-01 | 2010-12-29 | 山东省眼科研究所 | 一种伏立康唑眼内释药系统 |
BRPI0919668A2 (pt) | 2008-10-21 | 2018-05-29 | Onyx Therapeutics, Inc. | terapia de combinação com epóxi-cetonas de peptídeo |
CN101444510B (zh) * | 2008-12-31 | 2011-03-09 | 南京卡文迪许生物工程技术有限公司 | 含有伏立康唑的药物制剂及其制备方法 |
WO2011020605A1 (fr) | 2009-08-19 | 2011-02-24 | Ratiopharm Gmbh | Procédé de production de co-évaporats et de complexes comprenant un voriconazole et une cyclodextrine |
WO2011064558A2 (fr) | 2009-11-30 | 2011-06-03 | Cipla Limited | Composition pharmaceutique |
CN107049935A (zh) | 2010-06-29 | 2017-08-18 | 默沙东公司 | 取代β‑环糊精稳定的泊沙康唑静脉输注液制剂 |
EP2409699B1 (fr) * | 2010-07-23 | 2014-04-30 | Combino Pharm, S.L. | Compositions stables de voriconazole |
CN102058519B (zh) * | 2010-11-19 | 2013-01-02 | 苏州特瑞药业有限公司 | 一种伏立康唑缓释栓剂及其制备方法 |
EP2720723B1 (fr) | 2011-06-15 | 2018-04-11 | Synthon BV | Composition de voriconazole stabilisée |
EP2561863A1 (fr) | 2011-08-22 | 2013-02-27 | Farmaprojects, S.A.U. | Compositions pharmaceutiques comportant du voriconazole |
US20130202681A1 (en) * | 2012-01-05 | 2013-08-08 | Frederick Timothy Guilford | Liposomally encapsulated reduced glutathione for management of cancer and disruption of cancer energy cycles |
US8853248B2 (en) | 2012-04-05 | 2014-10-07 | Hubert Maehr | (1,2,3-triazolyl)sulfonyl derivatives |
CA2873044C (fr) | 2012-05-08 | 2021-01-26 | Onyx Therapeutics, Inc. | Methodes de complexation de cylodextrine servant a formuler des inhibiteurs de proteasome a peptide |
AU2013257830A1 (en) | 2012-05-11 | 2014-11-20 | Cipla Limited | Pharmaceutical composition |
EP2943224B1 (fr) | 2013-01-11 | 2020-01-01 | Xellia Pharmaceuticals ApS | Complexes d'inclusion de voriconazole |
CA2904670A1 (fr) | 2013-03-14 | 2014-09-13 | Fresenius Kabi Usa, Llc | Formulations de voriconazole |
GB201312737D0 (en) | 2013-07-17 | 2013-08-28 | Univ Greenwich | Cyclodextrin |
CN103690968A (zh) * | 2013-11-21 | 2014-04-02 | 石药集团中奇制药技术(石家庄)有限公司 | 一种伏立康唑组合物及其制备方法 |
PT109117B (pt) * | 2016-01-28 | 2019-02-01 | Hovione Farm Sa | Complexação de ingredientes ativos farmacêuticos |
EP3541364A1 (fr) | 2016-11-18 | 2019-09-25 | AiCuris Anti-infective Cures GmbH | Nouvelles formulations de composés de la famille des bêta-lactamines substitués par une amidine, à base de cyclodextrines modifiées et d'agents acidifiants, leur préparation et leur utilisation en tant que compositions pharmaceutiques antimicrobiennes |
US11040958B2 (en) | 2017-02-17 | 2021-06-22 | Wuhan Ll Science And Technology Development Co., Ltd. | Triazole antimicrobial derivative, pharmaceutical composition and use thereof |
CN113750034A (zh) * | 2020-06-05 | 2021-12-07 | 中南大学湘雅三医院 | 耳用温敏凝胶及其制备方法 |
CN116570558B (zh) * | 2023-06-21 | 2023-12-26 | 广州仁恒医药科技股份有限公司 | 一种伏立康唑眼用纳米缓释组合物及其制备方法和应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3346123A1 (de) | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
DE3347421A1 (de) | 1983-12-29 | 1985-07-11 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von fluorarmen alkaliphosphatloesungen |
GB8819308D0 (en) * | 1988-08-13 | 1988-09-14 | Pfizer Ltd | Triazole antifungal agents |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
US5278175A (en) * | 1990-02-02 | 1994-01-11 | Pfizer Inc. | Triazole antifungal agents |
GB9002375D0 (en) * | 1990-02-02 | 1990-04-04 | Pfizer Ltd | Triazole antifungal agents |
GB9512961D0 (en) * | 1995-06-26 | 1995-08-30 | Pfizer Ltd | Antifungal agents |
GB9602080D0 (en) | 1996-02-02 | 1996-04-03 | Pfizer Ltd | Pharmaceutical compounds |
-
1997
- 1997-06-21 GB GBGB9713149.4A patent/GB9713149D0/en active Pending
-
1998
- 1998-02-06 UA UA99126910A patent/UA57083C2/uk unknown
- 1998-05-05 TW TW087106918A patent/TW406023B/zh not_active IP Right Cessation
- 1998-06-02 KR KR10-1999-7012034A patent/KR100372988B1/ko not_active IP Right Cessation
- 1998-06-02 EP EP98930793.9A patent/EP1001813B8/fr not_active Expired - Lifetime
- 1998-06-02 ME MEP-1999-681A patent/ME00907B/me unknown
- 1998-06-02 EA EA199900937A patent/EA001924B1/ru not_active IP Right Cessation
- 1998-06-02 AT AT98930793T patent/ATE238812T1/de active
- 1998-06-02 HU HU0003323A patent/HU228338B1/hu unknown
- 1998-06-02 ES ES98930793T patent/ES2195355T3/es not_active Expired - Lifetime
- 1998-06-02 JP JP11503686A patent/JP2000513029A/ja not_active Withdrawn
- 1998-06-02 DK DK98930793T patent/DK1001813T3/da active
- 1998-06-02 NZ NZ501066A patent/NZ501066A/xx not_active IP Right Cessation
- 1998-06-02 CZ CZ19994096A patent/CZ289570B6/cs not_active IP Right Cessation
- 1998-06-02 SK SK1593-99A patent/SK282946B6/sk not_active IP Right Cessation
- 1998-06-02 US US09/402,289 patent/US6632803B1/en not_active Expired - Lifetime
- 1998-06-02 PL PL337692A patent/PL191295B1/pl unknown
- 1998-06-02 SI SI9830469T patent/SI1001813T1/xx unknown
- 1998-06-02 WO PCT/EP1998/003477 patent/WO1998058677A1/fr active IP Right Grant
- 1998-06-02 DE DE69814091T patent/DE69814091T2/de not_active Expired - Lifetime
- 1998-06-02 TR TR1999/03191T patent/TR199903191T2/xx unknown
- 1998-06-02 IL IL13291898A patent/IL132918A/en not_active IP Right Cessation
- 1998-06-02 CN CN98806446A patent/CN1125653C/zh not_active Expired - Lifetime
- 1998-06-02 BR BRPI9809468A patent/BRPI9809468B8/pt active IP Right Grant
- 1998-06-02 RS YUP-681/99A patent/RS49633B/sr unknown
- 1998-06-02 CA CA002295035A patent/CA2295035C/fr not_active Expired - Lifetime
- 1998-06-02 ID IDW991429A patent/ID22939A/id unknown
- 1998-06-02 PT PT98930793T patent/PT1001813E/pt unknown
- 1998-06-02 AU AU81104/98A patent/AU724799B2/en not_active Expired
- 1998-06-10 PA PA19988453201A patent/PA8453201A1/es unknown
- 1998-06-15 SA SA98190159A patent/SA98190159B1/ar unknown
- 1998-06-17 DZ DZ980133A patent/DZ2523A1/fr active
- 1998-06-17 MA MA25117A patent/MA26508A1/fr unknown
- 1998-06-17 TN TNTNSN98090A patent/TNSN98090A1/fr unknown
- 1998-06-18 AP APAP/P/1998/001268A patent/AP912A/en active
- 1998-06-18 AR ARP980102924A patent/AR015900A1/es active IP Right Grant
- 1998-06-19 PE PE1998000539A patent/PE84899A1/es not_active IP Right Cessation
- 1998-06-19 ZA ZA9805364A patent/ZA985364B/xx unknown
- 1998-06-19 UY UY25055A patent/UY25055A1/es not_active IP Right Cessation
- 1998-06-19 HR HR980341A patent/HRP980341B1/xx not_active IP Right Cessation
- 1998-06-20 MY MYPI98002792A patent/MY118151A/en unknown
- 1998-06-20 EG EG70998A patent/EG23910A/xx active
- 1998-06-23 CO CO98035641A patent/CO4940450A1/es unknown
-
1999
- 1999-11-12 NO NO19995565A patent/NO313125B1/no not_active IP Right Cessation
- 1999-11-15 BG BG103882A patent/BG64584B1/bg unknown
- 1999-11-15 IS IS5248A patent/IS2004B/is unknown
- 1999-12-10 OA OA9900277A patent/OA11232A/en unknown
-
2000
- 2000-11-17 HK HK00107329A patent/HK1027966A1/xx not_active IP Right Cessation
-
2002
- 2002-03-27 JP JP2002088076A patent/JP5089004B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN98090A1 (fr) | Formulations pharmaceutiques contenant du voriconazole, et procede pour leur preparation. | |
WO2001093841A3 (fr) | Analogues de l'acide barbiturique utilises comme agents therapeutiques | |
EA200000703A1 (ru) | Сульфонамидные производные в качестве пролекарств, ингибиторов аспартилпротеаз | |
TNSN97110A1 (fr) | Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MX9709094A (es) | Formulaciones farmaceuticas de derivados muy lipofilos de la comptotecina. | |
CA2421120A1 (fr) | Derives de quinolinone utilises comme inhibiteurs de la tyrosine kinase | |
BE899635A (fr) | Compositions pharmaceutiques. | |
IL104154A0 (en) | Saccharin derivatives,their preparation and pharmaceutical compositions containing them | |
UA41446C2 (uk) | Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі | |
TNSN97078A1 (fr) | Derives d'indole nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant | |
AU629977B2 (en) | 4-hydroxytetrahydropyran-2-ones and the corresponding dihydroxycarboxylic acid derivatives, salts and esters, process for their preparation, their use as pharmaceuticals, and pharmaceutical preparations and precursors | |
GB2334446B (en) | Aqueous compositions compromising a lipid and a lanolin-derived surfactant,and their use | |
YU92192A (sr) | Postupak za dobijanje preparata soli lipofilnih oligosaharidnih antibiotika | |
IT1314185B1 (it) | Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi | |
EA200000154A1 (ru) | Способ солюбилизации фармацевтически активных ингредиентов в воде и в водных носителях | |
TNSN99177A1 (fr) | COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1, 2-a] PYRAZINE ET PROCEDE POUR LEUR PREPARATION | |
TNSN00235A1 (fr) | Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant | |
IL83044A (en) | Diphenylpropanamines,their preparation and pharmaceutical compositions containing them | |
CA2396927A1 (fr) | Solutions d'acide ascorbique stabilisees, leur utilisation, leur procede de production et preparations les comprenant | |
BR9809492A (pt) | Composição farmacêutica aquosa injetável, e, processo para a preparação da mesma | |
EA200300406A1 (ru) | Фармацевтическая композиция дронедарона для парентерального введения | |
MA26725A1 (fr) | Derives de resorcinol, compositions pharmaceutiques les contenant et procede pour leur preparation | |
DE59610175D1 (de) | Hydantoinderivate als zwischenprodukte für pharmazeutische wirkstoffe | |
CA2383140A1 (fr) | Inhibiteurs de ppar.alpha. et ppar.gamma. | |
TR200003451T2 (tr) | Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları |